GlassScriptPhysician profile
Lisa M Moore
NPI 1689068751
$3,843.57
in general payments reported to CMS, 2019-2025
34 companies · $994 in 2025
The $994 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $795 · 2023: $867 · 2024: $417 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $803.38 | 2021-2024 | Prolate, Nalocet |
| Abbvie INC. | $381.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.02 | 2021-2024 | Relistor |
| Scilex Pharmaceuticals INC. | $265.91 | 2021-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $258.31 | 2021-2025 | Belbuca, Xtampza, Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $253.74 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $182.58 | 2024-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $177.16 | 2024-2025 | Fanapt, Hetlioz |
| Redhill Biopharma INC. | $158.08 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.88 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $110.75 | 2021-2025 | Uzedy |
| Biohaven Pharmaceutical Holding Company LTD. | $73.99 | 2022 | |
| Lilly USA, LLC | $70.90 | 2021-2023 | Emgality, Reyvow |
| Valinor Pharma, LLC | $61.73 | 2023-2024 | Movantik |
| Hikma Pharmaceuticals USA | $51.86 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $50.96 | 2024-2025 | Dyanavel Xr |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Virtus Pharmaceuticals LLC | $44.67 | 2023 | Levorphanol Tartrate |
| Indivior INC. | $42.77 | 2023-2024 | Sublocade |
| Idorsia Pharmaceuticals US INC | $34.78 | 2022-2023 | Quviviq |
| Protega Pharmaceutials INC | $31.72 | 2023 | Roxybond |
| Otsuka America Pharmaceutical, INC. | $30.90 | 2021-2024 | Rexulti |
| Pfizer INC. | $29.57 | 2021 | |
| Arbor Pharmaceuticals, INC. | $29.20 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.19 | 2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $19.68 | 2025 | Spravato |
| Corium, LLC | $17.57 | 2024 | Azstarys |
| Azurity Pharmaceuticals, INC. | $16.61 | 2023 | Horizant |
| Supernus Pharmaceuticals, INC. | $15.97 | 2025 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $15.81 | 2021 | |
| Lundbeck LLC | $14.65 | 2025 | Rexulti |
| Biodelivery Sciences International, INC. | $13.94 | 2021 | |
| Horizon Therapeutics Plc | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.